Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, I-70125 Bari, Italy.
Future Med Chem. 2018 Aug 1;10(16):1997-2018. doi: 10.4155/fmc-2018-0072. Epub 2018 Jul 3.
Identification of sigma-2 receptor (sig-2R) has been controversial. Nevertheless, interest in sig-2R is high for its overexpression in tumors and potentials in oncology. Additionally, sig-2R antagonists inhibit Aβ binding at neurons, blocking the cognitive impairments of Alzheimer's disease. The most representative classes of sig-2R ligands are herein treated with focus on compounds that served to study sig-2R biology and to produce sig-2R: fluorescent ligands; multifunctional anticancer agents; and targeting nanoparticles. Although fluorescent ligands serve as 'green' pharmacological tools, sig-2R-multifunctional conjugates and sig-2R-targeted nanoparticles show how sig-2R targeting increases the activity of anticancer drugs in tumors with reduced toxicity. Altogether, this review draws a picture of the multiple approaches of sig-2R ligands in cancer therapy and as Alzheimer's disease modifying disease agents.
sigma-2 受体(sig-2R)的鉴定一直存在争议。然而,由于其在肿瘤中的过度表达及其在肿瘤学中的潜力,人们对 sig-2R 的兴趣很高。此外,sig-2R 拮抗剂可抑制神经元上的 Aβ结合,阻断阿尔茨海默病的认知障碍。本文重点讨论了最具代表性的 sig-2R 配体类别,这些化合物用于研究 sig-2R 生物学和产生 sig-2R:荧光配体;多功能抗癌剂;以及靶向纳米颗粒。虽然荧光配体可用作“绿色”药理学工具,但 sig-2R-多功能缀合物和 sig-2R-靶向纳米颗粒表明,靶向 sig-2R 如何增加肿瘤中抗癌药物的活性,同时降低毒性。总的来说,这篇综述描绘了 sig-2R 配体在癌症治疗和作为阿尔茨海默病修饰疾病药物的多种方法。